Neuren Pharmaceuticals Statistics

Total Valuation

Neuren Pharmaceuticals has a market cap or net worth of AUD 1.59 billion. The enterprise value is 1.38 billion.

Market Cap	1.59B
Enterprise Value	1.38B

Important Dates

The next estimated earnings date is Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Neuren Pharmaceuticals has 127.82 million shares outstanding. The number of shares has increased by 0.15% in one year.

Current Share Class	n/a
Shares Outstanding	127.82M
Shares Change (YoY)	+0.15%
Shares Change (QoQ)	-0.51%
Owned by Insiders (%)	3.31%
Owned by Institutions (%)	17.76%
Float	110.82M

Valuation Ratios

The trailing PE ratio is 13.90 and the forward PE ratio is 16.07.

PE Ratio	13.90
Forward PE	16.07
PS Ratio	8.21
PB Ratio	7.25
P/TBV Ratio	n/a
P/FCF Ratio	13.30
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.86, with an EV/FCF ratio of 11.51.

EV / Earnings	11.73
EV / Sales	7.11
EV / EBITDA	8.86
EV / EBIT	8.87
EV / FCF	11.51

Financial Position

The company has a current ratio of 25.42

Current Ratio	25.42
Quick Ratio	25.42
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 75.51% and return on invested capital (ROIC) is 62.43%.

Return on Equity (ROE)	75.51%
Return on Assets (ROA)	59.56%
Return on Capital (ROIC)	62.43%
Revenue Per Employee	24.17M
Profits Per Employee	14.66M
Employee Count	8
Asset Turnover	1.19
Inventory Turnover	n/a

Taxes

In the past 12 months, Neuren Pharmaceuticals has paid 48.04 million in taxes.

Income Tax	48.04M
Effective Tax Rate	23.42%

Stock Price Statistics

The stock price has decreased by -15.79% in the last 52 weeks. The beta is 2.13, so Neuren Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	2.13
52-Week Price Change	-15.79%
50-Day Moving Average	13.91
200-Day Moving Average	17.78
Relative Strength Index (RSI)	36.51
Average Volume (20 Days)	802,616

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neuren Pharmaceuticals had revenue of AUD 193.34 million and earned 117.29 million in profits. Earnings per share was 0.89.

Revenue	193.34M
Gross Profit	160.44M
Operating Income	155.17M
Pretax Income	167.36M
Net Income	117.29M
EBITDA	155.19M
EBIT	155.17M
Earnings Per Share (EPS)	0.89

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	213.17M
Total Debt	n/a
Net Cash	213.17M
Net Cash Per Share	1.67
Equity (Book Value)	219.15M
Book Value Per Share	1.71
Working Capital	219.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 119.51 million and capital expenditures -25,000, giving a free cash flow of 119.49 million.

Operating Cash Flow	119.51M
Capital Expenditures	-25,000
Free Cash Flow	119.49M
FCF Per Share	0.93

Full Cash Flow Statement

Margins

Gross margin is 82.98%, with operating and profit margins of 80.25% and 60.67%.

Gross Margin	82.98%
Operating Margin	80.25%
Pretax Margin	86.56%
Profit Margin	60.67%
EBITDA Margin	80.27%
EBIT Margin	80.25%
FCF Margin	61.80%

Dividends & Yields

Neuren Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.15%
Shareholder Yield	-0.15%
Earnings Yield	7.19%
FCF Yield	7.52%

Stock Splits

The last stock split was on November 21, 2017. It was a reverse split with a ratio of 0.05.

Last Split Date	Nov 21, 2017
Split Type	Reverse
Split Ratio	0.05

Scores

Neuren Pharmaceuticals has an Altman Z-Score of 149.61 and a Piotroski F-Score of 6.

Altman Z-Score	149.61
Piotroski F-Score	6